Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease

医学 安慰剂 随机对照试验 背景(考古学) 甲状腺 内科学 胃肠病学 临床试验 内分泌学 病理 生物 古生物学 替代医学
作者
George Jean Kahaly,Peter J. Dolman,Jan Wolf,Bert C. Giers,Heike Maria Elflein,Amy Patel Jain,Ashok Srinivasan,Lubomir M. Hadjiiski,David R. Jordan,Elizabeth A. Bradley,Marius Nicolae Stan,Anja Katrin Eckstein,Susanne Pitz,Christian Vorländer,Sara Tullis Wester,John Nguyen,Nancy A. Tucker,Marco Sales‐Sanz,Steven E. Feldon,Christine C. Nelson
出处
期刊:The Journal of Clinical Endocrinology and Metabolism [Oxford University Press]
卷期号:108 (12): 3122-3134 被引量:79
标识
DOI:10.1210/clinem/dgad381
摘要

CONTEXT: Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED). OBJECTIVE: We report the first clinical studies of an FcRn inhibitor, batoclimab, in TED. DESIGN: Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials. SETTING: Multicenter. PARTICIPANTS: Patients with moderate-to-severe, active TED. INTERVENTION: In the POC trial, patients received weekly subcutaneous injections of batoclimab 680 mg for 2 weeks, followed by 340 mg for 4 weeks. In the double-blind trial, patients were randomized 2:2:1:2 to weekly batoclimab (680 mg, 340 mg, 255 mg) or placebo for 12 weeks. MAIN OUTCOME: Change from baseline in serum anti-TSH-R-Ab and total IgG (POC); 12-week proptosis response (randomized trial). RESULTS: The randomized trial was terminated because of an unanticipated increase in serum cholesterol; therefore, data from 65 of the planned 77 patients were analyzed. Both trials showed marked decreases in pathogenic anti-TSH-R-Ab and total IgG serum levels (P < .001) with batoclimab. In the randomized trial, there was no statistically significant difference with batoclimab vs placebo in proptosis response at 12 weeks, although significant differences were observed at several earlier timepoints. In addition, orbital muscle volume decreased (P < .03) at 12 weeks, whereas quality of life (appearance subscale) improved (P < .03) at 19 weeks in the 680-mg group. Batoclimab was generally well tolerated, with albumin reductions and increases in lipids that reversed upon discontinuation. CONCLUSIONS: These results provide insight into the efficacy and safety of batoclimab and support its further investigation as a potential therapy for TED.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
好困的应助被科研通管家采纳,获得10
刚刚
巴拉拉发布了新的文献求助10
刚刚
在水一方的应助被小太阳采纳,获得10
刚刚
天天快乐的应助被科研通管家采纳,获得10
1秒前
魔法少女完成签到,获得积分10
1秒前
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
初景发布了新的文献求助10
1秒前
顾矜的应助被科研通管家采纳,获得10
1秒前
小蘑菇的应助被科研通管家采纳,获得10
1秒前
null的应助被科研通管家采纳,获得10
1秒前
奔跑的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
Nole的应助被科研通管家采纳,获得10
1秒前
1秒前
2秒前
搜集达人的应助被科研通管家采纳,获得10
2秒前
酷波er的应助被科研通管家采纳,获得10
2秒前
molihuakai的应助被科研通管家采纳,获得10
2秒前
情怀的应助被科研通管家采纳,获得10
2秒前
2秒前
IDCY的应助被科研通管家采纳,获得30
2秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
2秒前
Jasper的应助被科研通管家采纳,获得10
2秒前
dlindl发布了新的文献求助10
2秒前
3秒前
汉堡包的应助被科研通管家采纳,获得10
3秒前
开心完成签到,获得积分10
3秒前
英姑的应助被科研通管家采纳,获得10
3秒前
传奇3的应助被科研通管家采纳,获得10
3秒前
慕青的应助被科研通管家采纳,获得10
3秒前
3秒前
看不懂英语完成签到,获得积分10
4秒前
wanci的应助被科研通管家采纳,获得10
4秒前
小马甲的应助被科研通管家采纳,获得10
4秒前
梵高晚风发布了新的文献求助10
4秒前
Orange的应助被科研通管家采纳,获得10
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176174
求助须知:如何正确求助?哪些是违规求助? 9567656
关于积分的说明 21793895
捐赠科研通 7770887
什么是DOI,文献DOI怎么找? 3431991
关于科研通互助平台的介绍 2556313
邀请新用户注册赠送积分活动 2477540